Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia

NCT ID: NCT01904864

Last Updated: 2017-12-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-07-31
• Study Completion Date: 2015-11-30

Brief Summary

This study is a randomized, controlled, double-blinded single center trial to compare the efficacy of NovaFerrum® to ferrous sulfate for the treatment of nutritional iron deficiency anemia (IDA) in infants and young children.

Hypothesis: NovaFerrum® has greater efficacy than ferrous sulfate in increasing hemoglobin concentration during a twelve week course of treatment to subjects with iron deficiency anemia.

Primary Aim:

To compare the efficacy of NovaFerrum® to ferrous sulfate for the treatment of nutritional IDA in infants and young children as determined by increase in hemoglobin concentration.

Secondary Aims:

1. To compare the adverse effects of treatment for IDA between ferrous sulfate and NovaFerrum®

2. To compare normalization of iron stores as demonstrated by laboratory measures of IDA (ferritin, TIBC, reticulocyte hemoglobin content) between subjects treated with ferrous sulfate or NovaFerrum®

3. To compare the adherence to study medication between subjects on ferrous sulfate and NovaFerrum®

4. To demonstrate efficacy of a once daily dosing regimen in the treatment of nutritional IDA

Detailed Description

Screening/Baseline Assessment (Week 0):

• History and Physical Examination:
• Detailed history regarding medical disorders predisposing to iron deficiency and diet (breast feeding, iron fortified formula, cow's milk), including total daily amount.
• Review of existing medical records (including blood counts and iron studies) submitted by primary care provider or recorded on Children's electronic medical record.
• History of pica and/or other sequelae from iron deficiency.
• Details regarding prior or current iron oral therapy (dose, preparation, timing, response) or recent blood transfusions.
• Comprehensive physical exam (PE) (baseline visit) consisting of vital signs, general, HEENT, cardio-respiratory, abdominal, extremities and skin; Focused PE (Weeks 4 and 12) consisting of vital signs, general, cardio-respiratory, abdominal and skin.
• Laboratory (Only #3 below for research only, not standard of care):

1. Complete blood count (CBC), reticulocyte count and reticulocyte hemoglobin content.

2. Serum ferritin, iron and total body iron capacity (TIBC).

Treatment Interventions:

• Patients who meet eligibility criteria and whose parents provide written informed consent will be randomized in a 1:1 ratio to receive either ferrous sulfate drops (15 mg/ml) or NovaFerrum® drops (15 mg/ml).
• Subjects will be assigned to receive a single daily dose of 3 mg/kg elemental iron. Timing of study drug will be at bedtime.
• As a part of standard care, patients will be advised to reduce cow milk intake to a maximum 16 oz. daily and not to give any milk after medication administration. There will be no other dietary modification prescribed by the study.
• Other iron containing medications (including vitamins) will be discontinued.
• Families will be asked to make a daily diary entry documenting administration and adverse effects and return the diary at follow-up clinic visits.

Follow-up Phone Contact (Weeks 2, 6, 10 - not standard of care)

• Phone contact with parents will be made biweekly between scheduled visits (e.g. Weeks 2, 6, and 10) to assess adverse effects, promote strict adherence and remind them of the next scheduled visit.

Assessment During Follow-up Visits at Weeks 4, 8, and 12 after Initiation of Therapy (Follow-up visits during weeks 4 and 12 are standard of care; Follow-up visit at week 8 is for research only):

• Review of interval history and diet by direct questioning of the parents and review of diary regarding adherence, adverse effects of iron therapy (e.g., refusal to take, spitting/vomiting, abdominal pain, constipation, black stools, stained teeth). The diary will also contain distracter items to assess background "noise".
• Recording of other medications or intercurrent illnesses.
• Laboratory studies at each follow-up visit: CBC with red blood cell (RBC) indices, (MCV, RDW) reticulocyte count, reticulocyte hemoglobin content, serum ferritin, serum iron and total iron binding capacity.
• Blood lead measurement at week 4 (research only). Will repeated only if abnormal.
• Focused physical exam at 4 and 12 week visits

Conditions

Iron Deficiency Anemia

Keywords

randomized controlled trial; iron medication; Anemia; Hematologic Disease; Anemia, Iron deficiency; anemia, nutritional; ferrous sulfate; NovaFerrum®

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

NovaFerrum®

Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks.

Group Type: ACTIVE_COMPARATOR

elemental iron (NovaFerrum®)

Intervention Type: DRUG

single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks

Ferrous Sulfate

Subjects randomized to this arm will receive a single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, ferrous sulfate, for 12 weeks.

Group Type: ACTIVE_COMPARATOR

elemental iron (Ferrous Sulfate)

Intervention Type: DRUG

single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks

Interventions

elemental iron (NovaFerrum®)

single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks

Intervention Type: DRUG

elemental iron (Ferrous Sulfate)

single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks

Intervention Type: DRUG

Other Intervention Names

Generic Name: polysaccharide iron vitamin mineral complex; Ferrous Sulfate

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 9 to < 48 months

2. IDA documented by hematologic indices (hemoglobin, MCV, RDW, reticulocyte count, reticulocyte hemoglobin content), serum ferritin, serum iron and total iron binding capacity

Exclusion Criteria

1. Iron deficiency likely or definitely due to blood loss from the intestine or other sites.

2. Evidence of response to recent/current oral iron therapy, as determined by increase in hemoglobin by > 1.0 gm/dL and MCV by 5 fL above measurements prior to iron therapy

3. History or evidence of intestinal malabsorption

4. History of prior intravenous iron therapy

5. Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination, or laboratory tests

6. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests.

7. High likelihood of suboptimal adherence by parents with study requirements (previous missed clinic visits)

8. Inability to tolerate oral medications

9. History of birth at < 30 weeks gestation

10. Other medical or social factors at discretion of treating physician

• Minimum Eligible Age: 9 Months
• Maximum Eligible Age: 48 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Gensavis Pharmaceuticals, LLC

UNKNOWN

Sponsor Role: collaborator

University of Texas Southwestern Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Patrick Leavey

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Patrick Leavey, MD

Role: PRINCIPAL_INVESTIGATOR

U Texas Southwestern

Locations

Children's Medical Center Dallas

Dallas, Texas, United States

Countries

United States

References

Powers JM, Buchanan GR, Adix L, Zhang S, Gao A, McCavit TL. Effect of Low-Dose Ferrous Sulfate vs Iron Polysaccharide Complex on Hemoglobin Concentration in Young Children With Nutritional Iron-Deficiency Anemia: A Randomized Clinical Trial. JAMA. 2017 Jun 13;317(22):2297-2304. doi: 10.1001/jama.2017.6846.

Reference Type: DERIVED

PMID: 28609534 (View on PubMed)

Other Identifiers

FE15929

Identifier Type: -

Identifier Source: org_study_id